November 27, 2017

Regeneron Study of Nesvacumab Discontinued

by

Regeneron Study of Nesvacumab Discontinued

It was recently reported here that nesvacumab (REGN910) was being tested in combination with Eylea (Regeneron) as a potential treatment for wet AMD. Regeneron, however, reported on November 27 that the results “did not provide sufficient differentiation to warrant Phase 3 development.” The Phase 2 trials have, therefore, been discontinued, and research data will be released at a future date.

We offer resources and free materials for those living with low vision.

View Resources

Related Articles

  • June 14, 2020

    Are some patients with CNV unresponsive to anti-VEGF?

    Since 2004, anti-VEGF drug injections have been shown to be highly effective in suppressing choroidal neovascularization (CNV) in the retinas of people with wet age-related macular degeneration and diabetic retinopathy. They have also been shown to suppress further CNV for as long as 12 weeks, depending upon the drug being used and the disease state […]

  • Telehealth usage increases during COVID-19

    A survey of 2,000 adults in the U.S. has shown that 42% have used telehealth services in place of their regular in-person visits to eye clinics since the beginning of the COVID-19 pandemic in March 2020. Telehealth is a service made available by way of telecommunication devices like computers and smart phones. Using this recent […]

  • Read All News